A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing

Oncotarget

Volumn 6, Issue 28, 2015, Pages 24884-24894

  Prapa, Malvina ^a   Caldrer, Sara ^b   Spano, Carlotta ^a   Bestagno, Marco ^c   Golinelli, Giulia ^a   Grisendi, Giulia ^a   Petrachi, Tiziana ^a   Conte, Pierfranco ^d   Horwitz, Edwin M ^e   Campana, Dario ^f   Paolucci, Paolo ^a   Dominici, Massimo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anti GD2 IgM derived; Chimeric antigen receptor; GD2; Neuroblastoma; T lymphocytes

Indexed keywords

ALDESLEUKIN; CD137 ANTIGEN; CD3 ZETA ANTIGEN; GAMMA INTERFERON; GANGLIOSIDE GD2; GANGLIOSIDE GD2 4 1BB CHIMERIC ANTIGEN RECEPTOR MONOCLONAL ANTIBODY; LYMPHOCYTE ANTIGEN; MONOCLONAL ANTIBODY; RETROVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; GANGLIOSIDE; GANGLIOSIDE, GD2; GREEN FLUORESCENT PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; TNFSF10 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL BASED GENE THERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOTOXICITY; MOUSE; NEUROBLASTOMA; NEUROECTODERM TUMOR; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SH SY5Y CELL LINE; SKNBE CELL LINE; T LYMPHOCYTE; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CYTOTOXICITY; DRUG SCREENING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD137; APOPTOSIS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GANGLIOSIDES; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, FLUORESCENCE; NEUROBLASTOMA; RECEPTORS, ANTIGEN, T-CELL; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944463280     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4670     Document Type: Article

References (32)

1. Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol. 2011; 21:229-37.
2. Newman EA, Lu F, Bashllari D, Wang L, Opipari AW, Castle V. Alternative NHEJ Pathway Components are Therapeutic Targets in High-risk Neuroblastoma. Mol Cancer Res. 2015; 13:470-82.
3. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Letters. 2014; 588:288-297.
4. Lin JJ, Huang CS, Yu J, Liao GS, Lien HC, Hung JT, Lin RJ, Chou FP, Yeh KT, Yu AL. Malignant phyllodes tumours display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells. Breast Cancer Res. 2014; 16:R29.
5. Suzuki M, Cheung NK. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets. 2015; 19:349-62.
6. Martinez C, Hofmann TJ, Marino R, Dominici M, Horwitz EM. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood. 2007; 109:4245-4248.
7. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985; 45:2642-9.
8. Yang RK, Sondel PM. Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs Future. 2010; 35:665.
9. Daly T, Royal RE, Kershaw MH, Treisman J, Wang G, Li W, Herlyn D, Eshhar Z, Hwu P. Recognition of human colon cancer by T-cells transduced with a chimeric receptor gene. Cancer Gene Ther. 2000; 7:284-91.
10. Haynes NM, Smyth MJ, Kershaw MH, Trapani JA, Darcy PK. Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by re-directed cytotoxic T-lymphocytes. Cancer Immunol Immunother. 1999; 47:278-86.
11. Maus MV, Grupp SA, Porter DL, June CH. Antibodymodified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014; 123:2625-35.
12. Occhino M, Raffaghello L, Burrone O, Gambini C, Pistoia V, Corrias MV, Bestagno M. Generation and characterization of dimeric small immunoproteins (SIPs) specific for neuroblastoma associated antigen GD2. Int J Mol Med. 2004; 14:383-388.
13. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Current Opinion in Immunology. 2009; 21:215-223.
14. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes. J. Exp. Med. 1998; 188:619-626.
15. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005; 12:933-41.
16. Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, Gao X, Guo L, Yvon E, Hicks J, Liu H, Dotti G, Metelitsa LS. Invariant NKT Cells with Chimeric Antigen Receptor Provide a Novel Platform for Safe and Effective Cancer Immunotherapy. Blood. 2014; 124:2824-33.
17. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, Campana D. Chimeric receptor with 4-1BB signalling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004; 8:676-684.
18. Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol. 1997; 158:2600-2609.
19. May KF Jr, Chen L, Zheng P, Liu Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 2002; 62:3459-3465.
20. Mogi S, Sakurai J, Kohsaka T, Enomoto S, Yagita H, Okumura K, Azuma M. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology. 2000; 101:541-547.
21. Kawalekar OU, Posey AD, Fraietta J, Lee J, Scholler J, Zhao Y, June CH. Distinct Signaling By Chimeric Antigen Receptors (CARs) Containing CD28 Signaling Domain Versus 4-1BB In Primary Human T Cells. Blood. 2013; 122.
22. Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int. J. Cancer. 2001; 94:228-236.
23. Yu J, Ren X, Li H, Cao S, Han Y, Enoki T, Kato I, Cao C, Hao X. Synergistic Effect of CH-296 and Interferon Gamma on Cytokine-Induced Killer Cells Expansion for Patients with Advanced-Stage Malignant Solid Tumors. Cancer Biotherapy and Radiopharmaceuticals. 2011; 26:485-494.
24. Schmeel FC, Schmeel LC, Gast SM, Schmidt-Wolf IGH. Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies. Int. J. Mol. Sci. 2014; 15:14632-14648.
25. Hombach AA, Rappl G, Abken H. Arming Cytokine- induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28-OX40 "Super-stimulation. The American Society of Gene & Cell Therapy. 2013; 21:2268-2277.
26. Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, Barrett DM, Zhao Y. Nature of Tumor Control by Permanently and Transiently Modified GD Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma. Cancer Immunol Res. 2014; 2:1059-70.
27. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney M, Foster AE. Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b. J Immunother. 2010; 33:780-788.
28. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis D, Spano C, Tagliazzucchi M, Barti-Juhasz H, Scarabelli L, Bambi F, Frassoldati A, et al. Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor-Related Apoptosis- Inducing Ligand Delivery for Cancer Therapy. Cancer Res. 2010; 70:3718-29.
29. Warrens AN, Jones MD, Lechler RI. Splicing by overlap extension by PCR using asymmetric amplification: an improved technique for the generation of hybrid proteins of immunological interest. Gene. 1997; 186:29-35.
30. López-Requena A, De Acosta CM, Bestagno M, Vázquez AM, Pérez R, Burrone OR. Gangliosides, Ab1 and Ab2 antibodies IV. Dominance of VH domain in the induction of anti-idiotypic antibodies by gene gun immunization. Molecular Immunology. 2007; 44:3070-3075.
31. Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, June CH, Wagner JE, Blazar BR, Zhou X. 4-1BB and CD28 signaling plays a synergistic role in redirecting Umbilical Cord Blood T Cells against B-Cell Malignancies. Human Gene Therapy. 2010; 21:75-86.
32. Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A. Calcein-Acetyoxymethyl Cytotoxicity Assay: Standardization of a Method Allowing Additional Analyses on Recovered Effector Cells and Supernatants. Clin Diagn Lab Immunol. 2001; 8:1131-1135.